Американское общество гирудотерапии

Tissue factor pathway inhibitor.

Review published in Minerva medica (1999)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewРазработка лекарственных препаратовФармакология секрета слюнных желёзCamici et al. · Minerva medica, 1999

Abstract

The role of Tissue Factor (TF, thromboplastin) as the major factor in initiation of the blood coagulation process has been known for more than 100 years. Its importance for the development of clinical thrombosis, be it venous or arterial, and the complexity of the cell biology of TF, have however been increasingly appreciated over the past 15-20 years. Acting as a cofactor for coagulation factor VIIa, it is now clear that TF is able to activate factor IX. Aberrant expression of TF seems to play a major role in the intravascular coagulations disorders linked to endotoxemia, malignancies, immunological diseases and atherosclerosis. Tissue Factor Pathway Inhibitor (TFPI) is the natural direct inhibitor of TF/FVIIa complex. In this study the physiological role, mechanism of action and pharmacological potential of TFPI are discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsHeparinHumansLipoproteins

Резюме

The role of Tissue Factor (TF, thromboplastin) as the major factor in initiation of the blood coagulation process has been known for more than 100 years. Its importance for the development of clinical thrombosis, be it venous or arterial, and the complexity of the cell biology of TF, have however...

Почему это важно для гирудотерапии

This review discusses the physiological role, mechanism of action, and pharmacological potential of Tissue Factor Pathway Inhibitor (TFPI), the natural direct inhibitor of the TF/FVIIa complex, in the context of tissue factor's central role in initiating blood coagulation and its involvement in intravascular coagulation disorders. For ASH, this article has no defensible relevance: the abstract contains no mention of leeches, hirudotherapy, or any leech-derived compound. The study reviews a mammalian endogenous anticoagulant pathway with no connection to the leech secretome or ASH's domain. While TFPI represents an anticoagulant mechanism, the abstract does not draw any link to leech biology or hirudotherapy.

Цитирование

Tissue factor pathway inhibitor.

Camici et al. · Minerva medica, 1999

Связанный клинический контекст

Добавлено в библиотеку ASH: May 28, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.